A comparative study on systemic pharmacodynamic effects of two HFA formulations of salmeterol xinafoate, in healthy subjects

S. Chandran, N. Morde, J. Rebello, S. Chachad, S. Purandare, G. Malhotra, A. Lulla (Mumbai, India)

Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Session: Drug delivery and pharmacokinetics I
Session type: E-Communication Session
Number: 2034
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Chandran, N. Morde, J. Rebello, S. Chachad, S. Purandare, G. Malhotra, A. Lulla (Mumbai, India). A comparative study on systemic pharmacodynamic effects of two HFA formulations of salmeterol xinafoate, in healthy subjects. Eur Respir J 2010; 36: Suppl. 54, 2034

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pharmacokinetic evaluation of two HFA pMDI formulations of salmeterol xinafoate administered through a spacer in healthy subjects
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

A comparative study of the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of salmeterol HFA and CFC MDI inhalers in healthy subjects
Source: Eur Respir J 2004; 24: Suppl. 48, 582s
Year: 2004

Comparison of pulmonary and systemic absoption of two HFA formulations of salmeterol in healthy subjects
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008

Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once daily inhalation as a fixed-dose combination in healthy subjects
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019


Evaluation of the systemic pharmacodynamic effects of two HFA formulations of Salmeterol xinafoate/Fluticasone propionate HFA pMDI 25/250 mcg
Source: International Congress 2017 – Inhalers and their use
Year: 2017

24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol
Source: Annual Congress 2008 - New treatments for asthma
Year: 2008

Budesonide HFA pMDI is pharmacokinetically and clinically comparable with budesonide CFC pMDI in healthy volunteers, and in adults and children with asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 503s
Year: 2005

Budesonide pharmacokinetics and systemic effects at steady state via HFA pMDI, CFC pMDI and Turbuhaler® in healthy volunteers
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008


Pharmacokinetic and pharmacodynamic characteristics of HFA and CFC pMDI formulations of budesonide
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010


Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 207s
Year: 2006

Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate as a fixed-dose combination in Japanese and Caucasian healthy subjects
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019


Clinical equivalence of two HFA formulations of salmeterol xinafoate in asthmatic patients using 12 hour serial spirometry
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

Pharmacokinetic bioequivalence of inhaled CHF 1535 50/6 vs. the free combination of beclomethasone and formoterol in asthmatic children
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Bronchoprotective and anti-inflammatory effect of beclometasone dipropionate plus formoterol HFA fixed combination in asthmatic patients
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
Source: Eur Respir J 2014; 43: 763-772
Year: 2014



Pharmacokinetics and pharmacodynamics of a new beclomethasone dipropionate and formoterol CFC-free fixed combination in healthy volunteers
Source: Eur Respir J 2006; 28: Suppl. 50, 667s
Year: 2006

Population pharmacokinetics of nebulized arformoterol in subjects with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 427s
Year: 2006